| アブストラクト | OBJECTIVE: To analyze and compare the incidence of adverse events (AEs) associated with different administration routes of colistin, with the aim of providing a reference for its safe and effective clinical use. METHODS: Adverse event (AE) reports related to colistin were retrieved from the FDA Adverse Event Reporting System (FAERS) database. The reporting trends were analyzed, and the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) for colistin-associated AEs were calculated. A comparative analysis was conducted to examine the occurrence of AEs under different administration routes of colistin. RESULTS: A total of 13,043 AE reports were extracted from the FAERS database. Further analysis of 176 key AEs associated with colistin indicated a significant increase in the number of reports after 2021. The year and country of the reports showed heterogeneity across different administration routes. Intravenous (IV) administration of colistin was associated with the highest proportion of AEs, and heterogeneity was also observed in the types of AEs reported for inhaled and oral (PO) administration routes. CONCLUSION: Compared to inhaled and PO administration routes, IV administration of colistin is more likely to result in AEs such as nephrotoxicity and drug ineffectiveness. Additionally, there are significant differences in the types of AEs associated with colistin across different administration routes. |
|---|
| ジャーナル名 | Scientific reports |
|---|
| Pubmed追加日 | 2025/3/27 |
|---|
| 投稿者 | Xu, Pengtao; Xu, Lili; Ji, Hui; Song, Yibo; Zhang, Keying; Ren, Xiuying; Tang, Zhihua |
|---|
| 組織名 | Department of Pharmacy, Shaoxing People's Hospital, Shaoxing, 312000, Zhejiang,;People's Republic of China.;People's Republic of China. 12319096@zju.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40140483/ |
|---|
